Pharming announces marketing authorization in the U.K. for Joenja® (leniolisib)
September 26, 2024 01:00 ET
|
Pharming Group N.V.
For media and investors only Indicated for adult and pediatric patients 12 years of age and older with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) Leiden, the...
Mesoblast Partner JCR Pharmaceuticals Receives Recommendation For Approval Of Mesenchymal Stem Cell Product In Japan
September 03, 2015 20:44 ET
|
Mesoblast
NEW YORK and MELBOURNE, Australia, Sept. 3, 2015 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX: MSB; USOTC: MBLTY) today announced that the allogeneic mesenchymal stem cell-based regenerative medicine...